Ciplactin

Quick links to important sections

Ciplactin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciplactin

Property Description
Active ingredient Cyproheptadine Hydrochloride
Form Oral Tablet, Oral Syrup
Pharmacological Class First-Generation H1-Receptor Antagonist, Antiserotonergic Agent
Common Type Prescription-only Medication
Origin Synthetic (Piperidine derivative)

What Type of Medicine is Ciplactin (Cyproheptadine)?

Ciplactin is the trade name for a synthetic pharmaceutical compound whose active ingredient is Cyproheptadine Hydrochloride, a prescription-only medication classified as a first-generation antihistamine. This drug is a single-ingredient product derived chemically from piperidine and is approved for oral ingestion. This classification defines it as an older compound that is clinically recognized for readily interacting with the central nervous system, distinguishing it from newer, peripherally acting compounds.

Beyond its primary function as an H1-receptor antagonist, Cyproheptadine is also a potent antiserotonergic agent, acting to compete with both histamine and serotonin at their respective receptor sites.


Composition and Available Forms of Cyproheptadine

The active compound in the medicine is Cyproheptadine Hcl, and the product is manufactured as an oral formulation available in both a solid tablet form and a liquid syrup. The tablets utilize solid excipients, while the syrup provides the active Cyproheptadine Hydrochloride dissolved in an aqueous liquid vehicle. The provision of both a tablet and a syrup ensures flexibility in administration through the standard oral route, accommodating diverse patient needs.


High-Level Purpose and Mechanism (General Benefit)

Cyproheptadine’s general pharmacological purpose is to counter physiological responses mediated by endogenous chemicals, yielding a reliable benefit through its dual antagonistic action. It functions by blocking the effects of histamine released in the body. Additionally, its serotonin antagonism allows it to interfere with specific neural pathways. Its mechanism results in a sedative effect due to its ability to cross the blood-brain barrier. The overall benefit of these actions is the comprehensive modulation of these chemical messengers, resulting in the general counteraction of histamine-driven responses and the pharmacological utility of its inherent calming properties.

Regulatory References

  1. Cyproheptadine: MedlinePlus Drug Information

What side effects are possible with Ciplactin?

Possible Side Effects and Safety Information

Ciplactin (Cyproheptadine) is associated with adverse reactions that primarily affect the central nervous system, with drowsiness and sedation being the most frequently reported. Other common effects include dizziness, disturbed coordination, dry mouth, blurred vision, and constipation.

Serious and Clinically Significant Adverse Reactions

Although rare, severe adverse reactions have been documented. These include anaphylactic shock, hemolytic anemia, hepatic failure, and convulsions (seizures). Other serious effects can involve the cardiovascular system (e.g., hypotension, tachycardia) and the urogenital system (e.g., urinary retention, difficulty urinating). Patients should seek immediate medical attention if signs of these reactions occur, such as yellowing of the skin/eyes, unexplained bleeding, or difficulty passing urine.

Safety Restrictions and Population Considerations

Ciplactin is contraindicated in several conditions due to the risk of exacerbating the underlying issue. These include narrow-angle glaucoma, symptomatic prostatic hypertrophy, bladder neck obstruction, and stenosing peptic ulcer. The medication must not be used concurrently with Monoamine Oxidase (MAO) inhibitors.

Caution is advised in patients with a history of bronchial asthma, cardiovascular disease, hypertension, or hyperthyroidism. Due to increased susceptibility to central nervous system effects, use is contraindicated in premature or newborn infants and generally not recommended for children under two years of age. Elderly and debilitated patients may experience a greater risk of sedation, dizziness, and low blood pressure. Due to the potential for impaired mental alertness, patients are advised against operating machinery or driving until they know how the drug affects them.

Overdose and Emergency Response

The documented manifestations of Cyproheptadine overdosage relate primarily to its effects on the central nervous system (CNS) and its anticholinergic properties. Overdose presentation may range from deep CNS depression, resulting in profound drowsiness or unresponsiveness, to paradoxical CNS stimulation, including restlessness, agitation, and hallucinations. Characteristic atropine-like signs may also be present, such as fixed and dilated pupils, dry mouth, and flushing of the skin.

Severe and life-threatening outcomes officially documented in regulatory information include convulsions, respiratory arrest, cardiac arrest, and death. Infants and young children are explicitly identified as a vulnerable population, facing an increased risk of these severe and fatal outcomes following an overdose.

If an overdosage is suspected, immediate medical attention is required. The official guidance states that emergency services must be called immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management procedures officially described focus on supportive and symptomatic treatment. These measures may include gastric lavage using isotonic or half-isotonic saline, followed by the administration of activated charcoal. While no specific antidote is broadly described, physostigmine salicylate is sometimes listed as a consideration for life-threatening CNS signs.

Therapeutic Uses of Ciplactin

This medication is commonly used in areas where short-term symptom management is appropriate and is applied across domains where additional symptomatic support is needed. It is considered relevant in contexts involving heightened systemic burden.

Relief for Allergic and Hypersensitivity Symptoms

This medication is commonly used to help with symptom clusters that may become intense or disruptive associated with allergic conditions like urticaria (hives) and rhinitis (hay fever). It is relevant for managing symptoms that interfere with daily comfort, such as intense itching (pruritus), skin swelling, and mucocutaneous irritation. This supportive relief supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.


Support for Appetite and Preventative Management

Ciplactin is also applied in clinical settings marked by the functional difficulty of inadequate eating, serving as a supportive therapeutic tool for appetite stimulation. It is relevant in situations where patients, including children, experience a significant loss of appetite (anorexia), and the relevant benefit may assist with the promotion of caloric intake, which supports general well-being during symptomatic phases. Furthermore, the medication is used for managing symptoms related to increased neurological activity, relevant for easing recurrent or episodic manifestations like migraine headaches. This may be part of symptomatic management, assisting with maintaining functional stability.

Quick Fact: Relief for Pruritus and Appetite Loss Used across domains where short-term symptom management is appropriate, this drug is commonly used to help with symptom clusters that may become intense or disruptive, supporting general well-being and easing discomfort from persistent itching.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ciplactin — Official Regulatory Information


Eligibility Scope

Classification Allowed/Restricted Populations
Populations for whom use is allowed (as stated in label) Adults and adolescents 15 years old; Children aged 2–14 years, provided there are no contraindications.
Populations for whom use is contraindicated Newborn or premature infants; Nursing Mothers; Elderly, debilitated patients; Patients with known hypersensitivity; Patients undergoing therapy for an acute asthmatic attack.
Age-related eligibility rules Contraindicated in infants; Safety and effectiveness have not been established for children below the age of two years. Dosage for the elderly must be cautious (starting at the low end).
Condition-specific eligibility rules (Absolute Contraindications) Angle-closure glaucoma; Stenosing peptic ulcer; Pyloroduodenal obstruction; Symptomatic prostatic hypertrophy; Bladder neck obstruction.
Pregnancy and lactation eligibility status Pregnancy: Use is permitted only if clearly needed (Category B status). Lactation/Breastfeeding: Contraindicated in nursing mothers.
Eligibility-related restrictions (Use with Caution required) Patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, or hypertension.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Prohibited), Use Not Established (Restricted), Use With Caution (Conditional).

Regulatory basis: U.S. National Institutes of Health (NIH) DailyMed Prescribing Information and corresponding national regulatory documents.

Connection to the overall eligibility profile: Official regulatory documents strictly define who can and cannot use Ciplactin by classifying specific populations and underlying conditions as absolute contraindications or conditions requiring use with caution. This structure prohibits use in newborns, nursing mothers, and individuals with specific obstructive conditions, while permitting use for adults and children over two years old only if no such prohibitions are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Restrictions and Warnings

Ciplactin (Cyproheptadine) has documented interactions that are classified based on the resulting pharmacodynamic effects when co-administered with certain substances and drug classes, as specified in regulatory labeling.

Contraindicated Combination

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This combination is documented to prolong and intensify the anticholinergic effects of Cyproheptadine, leading to an increased risk of toxicity.

Pharmacodynamic Additive Effects

The medicine may have clinically significant additive effects when co-administered with other Central Nervous System (CNS) Depressants. These agents include sedatives, hypnotics, and tranquilizers. The combined use with these substances, as well as with alcohol (ethanol), may result in enhanced CNS depression, leading to increased drowsiness and potential impairment of mental alertness.

Population-Specific Constraint

Use is formally contraindicated in elderly or debilitated patients. This restriction is based on the heightened risk in this population of increased central nervous system and anticholinergic side effects resulting from interaction effects.

Mechanism of Action

How Ciplactin works

Ciplactin, containing the compound cyproheptadine, is a pleiotropic medication that primarily acts as a competitive antagonist at several key neurochemical receptors to exert its effects. This mechanism involves modulating activity across multiple distinct signaling pathways.


Antagonism of Histamine H1 Receptors

The compound binds to and blocks the H1 receptor, inhibiting the action of histamine, a key inflammatory mediator. This action inhibits the signaling sequences initiated by histamine binding, thereby modulating excessive mediator activity in affected biological systems.


Serotonin Receptor Modulation

Cyproheptadine engages mechanisms involving serotonin through antagonism of the 5-HT 2A and 5-HT 2C receptor subtypes. This anti-serotonergic activity in the central nervous system modifies the molecular steps that influence pathways associated with hypothalamic regulation of energy balance.


Muscarinic Acetylcholine Receptor Blockade

Ciplactin further exhibits anticholinergic properties by blocking muscarinic acetylcholine receptors in various tissues. Engaging this mechanism supports the regulation of processes driven by parasympathetic signaling patterns, resulting in downstream effects on smooth muscle activity and exocrine gland secretions.

Dosage and Administration Information

How to Use Ciplactin: Official Administration Guidelines

Ciplactin, whose active ingredient is Cyproheptadine Hydrochloride, is approved for use exclusively via the oral route. It is supplied as a 4 mg tablet and a 2 mg/5 mL oral syrup, enabling flexible oral administration. The administration protocol emphasizes dose individualization while strictly adhering to official maximum limits.


Standard Dosing and Frequency

The dosage must be administered in divided doses throughout the day. This schedule is mandated because the symptomatic effect of a single dose generally lasts only four to six hours.

Population Typical Starting Dose Maximum Daily Dose (Limit)
Adults 4 mg three times a day (TID) 32 mg/day or 0.5 mg/kg/day
Children (7–14 years) 4 mg two or three times a day 16 mg/day
Children (2–6 years) 2 mg two or three times a day 12 mg/day

Administration Context and Special Conditions

Administration is generally flexible regarding meal timing, as the medication can be taken with or without food.

For the oral syrup formulation, accurate measurement is a procedural requirement. Patients must use a calibrated measuring device to ensure the dose matches the physician's prescription. For older adults and patients with decreased renal function, official guidelines suggest using the lower end of the established dosage range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciplactin (Cyproheptadine)


Evidence for Symptom Management in Allergic Conditions

Ciplactin has been extensively evaluated in studies exploring how symptoms change over time for conditions characterized by episodic or acute manifestations, such as hives (urticaria) and allergic rhinitis. Research primarily includes Randomized Controlled Trials (RCTs), systematic reviews, and consensus reports, which is consistent with the evidence base for a long-established compound. These trials focused on outcomes related to physical discomfort, monitoring changes using standardized scales and questionnaires examining patient-reported outcomes describing perceived discomfort and daily functioning.

Research so far indicates patterns related to symptom control in patients, including those whose conditions involving periods of heightened symptoms did not fully respond to newer, second-generation antihistamines. Findings describe patterns observed in these studies, contributing to the understanding of symptom control during phases of heightened symptom activity. The evidence base aligns with its classification as a first-generation H1-antihistamine.

What remains uncertain is the extent of data from large-scale, contemporary RCTs across all allergic populations compared to the trials available for newer compounds. The research base mostly explores short-term symptom changes, meaning that long-term patterns regarding symptom changes over many months are not fully established or comprehensively characterized by existing studies.


Evidence for Appetite Stimulation and Weight Gain

Research has explored Ciplactin's role in contexts involving functional difficulty, such as anorexia or inadequate eating, where the research goal is to examine outcomes related to changes in caloric consumption. Study designs have included a mix of placebo-controlled and cross-over Randomized Controlled Trials (RCTs), often supplemented by retrospective chart reviews. Research examined outcomes related to systemic or functional imbalance, such as changes in body weight and detailed measures of caloric intake and feeding behaviors.

Studies report how symptoms evolved in the observed populations, and findings describe patterns of weight changes and increased caloric consumption that were associated with the medication in some studies. This effect was observed in some studies involving diverse groups, including children with various causes of undernourishment and adults with specific subtypes of anorexia. The overall evidence is generally categorized by researchers as limited to moderate, based on its investigation in multiple, smaller-scale trials.

Key Studies & References

  1. Cyproheptadine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Ciplactin (FAQ)


Q: How quickly does Ciplactin usually start working?

Official medication fact sheets generally describe that the effects of Ciplactin (Cyproheptadine) may begin to be noticeable within 30 to 60 minutes after administration. The exact onset time can vary based on the individual and the condition being addressed.


Q: How long do the effects of Ciplactin typically last?

According to official documentation, the symptomatic effect of a single dose of Ciplactin usually lasts for four to six hours. This relatively short duration is why the medication is typically administered in multiple, divided doses throughout the day.


Q: How often is Ciplactin typically taken according to standard guidelines?

Standard guidelines emphasize that the medication is administered in divided doses to maintain its effect, meaning it is typically taken two or three times a day. The specific frequency is determined by a healthcare professional based on the individual's needs.


Q: Does taking Ciplactin at night help with certain side effects?

Ciplactin commonly causes drowsiness or sedation. Informational resources sometimes note that taking the dose closer to bedtime may help minimize disruption to daytime activities caused by these central nervous system effects. Any changes to the timing of administration are subjects for a discussion with a healthcare provider.


Q: Are there official descriptions of Ciplactin's effect on blood pressure?

Yes, official safety documents advise caution for patients with hypertension (high blood pressure) or cardiovascular disease. In rare cases, severe adverse reactions can include hypotension (low blood pressure).


Q: What is the maximum number of days Ciplactin can be taken continuously, based on official guidelines?

Regulatory documents specify maximum daily doses but do not typically set a strict limit on the number of days the medication can be taken continuously. The appropriate length of treatment is determined by the prescribing doctor based on the condition being treated and the patient's response.


Q: Can Ciplactin interact with birth control pills?

While official interaction warnings focus on other drug classes like MAOIs and CNS depressants, general drug information sources often indicate that Ciplactin does not affect the efficacy of birth control pills. Verification regarding specific medication combinations is typically done by a healthcare provider.


Q: Can Ciplactin be taken with food, or must it be taken on an empty stomach?

Official administration instructions state that Ciplactin can generally be taken with or without food. The administration is flexible regarding food timing. Some patients find that taking medication with food can help manage potential mild gastrointestinal discomfort.


Q: Is Ciplactin used for anything besides allergies or skin conditions?

Yes, regulatory approvals for the active ingredient extend beyond allergic conditions like hay fever (allergic rhinitis) and hives (urticaria). The medication is also approved for use as an appetite stimulant in individuals experiencing a loss of appetite.


Q: Why is Ciplactin sometimes referred to in discussions about weight gain?

The drug's active ingredient has recognized appetite-stimulating effects, a characteristic supported by research literature. This effect can be associated with increased caloric intake and subsequently, weight gain, particularly when the drug is used to treat appetite loss or undernourishment.


Q: What kind of side effects are common with Ciplactin?

Common side effects are often related to the central nervous system (CNS), including drowsiness, sedation, and impaired coordination. Other frequent effects are anticholinergic in nature, such as dry mouth, blurred vision, and constipation.


Q: Do all official sources list the same common side effects for Ciplactin?

Although minor differences in language may exist, major regulatory bodies, such as the FDA and EMA, generally harmonize on the most common and serious adverse reactions listed in their official labeling. This ensures core safety information remains consistent across authoritative sources.


Q: Are there any common foods or supplements that interact with Ciplactin?

Official warnings emphasize interactions with other medications and alcohol (ethanol) due to enhanced CNS depression. General drug guides often state there are no known specific drug-food interactions for the active ingredient. It is customary to disclose the use of all supplements to a healthcare provider.


Q: Is it common for people to feel very thirsty when taking Ciplactin?

While thirst itself may not be explicitly listed, official side effect lists commonly include dry mouth (xerostomia). Dry mouth is a common anticholinergic effect of the medication that can often lead to an increased sensation of thirst.


Q: Can Ciplactin affect energy levels?

Yes, official safety documents report that Ciplactin is commonly associated with side effects such as drowsiness, tiredness, and weakness. These effects are linked to the drug's activity in the central nervous system and can reduce a person's typical energy levels.


Q: Is there a difference in how Ciplactin and other common allergy medicines are described?

Yes, official classifications describe Ciplactin's active ingredient as a first-generation H1-antihistamine. This class of medicine is known to readily affect the central nervous system, distinguishing it from newer, second-generation antihistamines, which typically cause less sedation.


Q: What is the mechanism of action of Ciplactin according to official descriptions?

Official documents describe the active ingredient as a competitive antagonist primarily blocking the Histamine H1-receptor. It also features significant activity as an antiserotonergic agent, blocking certain serotonin receptors, which contributes to its broad effects on the body.


Q: What should I know if I miss a standard dose of Ciplactin?

General regulatory guidance indicates that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose is typically skipped rather than taking two doses close together. The regular schedule should then be followed.


Q: Are there research studies looking at the long-term use of Ciplactin?

The current evidence base primarily includes studies that examine short-term symptom changes related to the drug's use. Research on the long-term patterns of symptom changes and effects over many months is described in the literature as not fully established or comprehensively characterized.


Q: Is Ciplactin associated with any risk of dependence?

According to official product information and drug guides, Ciplactin (Cyproheptadine) is not generally classified as an addictive or habit-forming substance.


Q: Why might a doctor prescribe Ciplactin for something other than allergies?

Official regulatory documents permit the use of the drug's active ingredient as an appetite stimulant. This means a healthcare professional may prescribe it to help increase appetite in individuals experiencing undernourishment or appetite loss.


Q: What is the half-life of Ciplactin described as in pharmacologic sources?

Pharmacologic sources describe the half-life of the active ingredient, Cyproheptadine, as typically ranging from 1 to 4 hours. The half-life refers to the time it takes for the amount of drug in the body to reduce by half.


Q: Does Ciplactin have any known effects on laboratory test results?

Yes, official safety information indicates that Ciplactin may interfere with the results of certain diagnostic tests, specifically potentially causing a false report for diagnostic antigen skin tests.


Q: Is Ciplactin known to interact with herbal remedies?

Official drug interaction databases note that the active ingredient is a CNS depressant, and combining it with certain herbal or plant-derived products like Cannabis may increase the risk of additive CNS depression. It is customary to disclose the use of all supplements and herbal remedies to a healthcare provider to ensure all potential interactions are considered.


Q: Is it normal to experience dizziness when starting Ciplactin?

Yes, dizziness is listed in official documents as a common adverse reaction associated with the medication. It is a known effect that patients may experience, particularly when first starting treatment or when the dosage is changed.


Q: Do studies suggest Ciplactin affects hormone levels?

Research has been conducted that suggests Ciplactin's active ingredient may affect certain hormone levels. Studies indicate that it can inhibit the secretion of hormones like human growth hormone and cortisol during sleep, possibly due to its action on serotonin receptors.


Q: Is Ciplactin generally available over-the-counter or only by prescription?

In the United States, Ciplactin is classified as a prescription-only medication ( Rx-only). Regulatory classification in other countries may vary, but in the US, it requires a prescription.

How should Ciplactin be stored and disposed of?

How to Store and Dispose of Ciplactin?

The storage and disposal of Ciplactin (cyproheptadine hydrochloride) must adhere to the conditions documented in official regulatory labeling.

Required Storage Conditions

Item Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 mathrmC to 25 mathrmC)
Protection Protect from excess moisture; oral solution must not be frozen.
Child Safety Must be stored out of the reach of children.

Disposal Instructions

Unused or expired Ciplactin must be handled according to specific regulatory guidance to protect the environment and prevent misuse. Disposal should be managed through an official drug take-back program or mail-back service. The medicine should not be flushed down the toilet or disposed of in wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ciplactin found in:

A-Z Index: